Latest Breaking News On - திரவ உயிர் அறிவியல் - Page 1 : comparemela.com

IV BioHoldings : Debuts Liquid Biopsy Portfolio; Partners with P4 Diagnostix to Scale Commercialization of Non-Invasive Lung, Liver and Breast Diagnostics

IV BioHoldings : Debuts Liquid Biopsy Portfolio; Partners with P4 Diagnostix to Scale Commercialization of Non-Invasive Lung, Liver and Breast Diagnostics
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesElizabeth cormierMarcus cognettiMarty keiserLiquidlung incHepgene incMammogen incLiquid biosciencesElizabeth cormier mayLong island pathologyPlatinum pathologyMetamark laboratoriesஒன்றுபட்டது மாநிலங்களில்எலிசபெத் கார்மிர்தியாகி கேசேர்திரவ உயிர் அறிவியல்

Global Capital Network (GCN) features GATC Health as medtech impact brand to consider as a strategic partner for Family Offices, Angel Investors, Venture Capital & PE

Global Capital Network (GCN) features GATC Health as medtech impact brand to consider as a strategic partner for Family Offices, Angel Investors, Venture Capital & PE Share Article Recently, GATC & Liquid Biosciences signed a partnership agreement that combines Liquid Biosciences’ evolutionary math and GATC’s artificial intelligence focused on predictive multiomics known as Multiomics Advanced Technology™ Next Generation Medtech Platform This impactful medical AI technology and JV can significantly reduce drug development costs & personalize healthcare. We want to highlight it as a strategic partnership opportunity to private & institutional capital sources around the world - Josh Bois, CEO Global Capital Network IRVINE, Calif. (PRWEB)

Josh boisPatrick lilleyJohn strohMultiomic advanced technologyHealth has to sayMultiomics advanced technologyMedia contactGlobal capital networkNext generation medtechLiquid biosciencesLiquid biosystemsCollaboration will entailPredictive multiomicsAngel investorsFamily officesVenture capital

Veteran Biotechnology Executive Elizabeth Cormier-May Recruited to Lead Women s Health Startup Mammogen Inc

Share this article Share this article ALISO VIEJO, Calif., Feb. 4, 2021 /PRNewswire/ Mammogen, Inc., a women s health startup born at the intersection of data, technology and science, and Bench International, a leading global executive search firm, jointly announce the appointment of Elizabeth Cormier-May as Chief Executive Officer and member of the board of directors of Mammogen. She will begin her new role on March 1 st, 2021. In her new role, Cormier-May will lead efforts to develop, validate and commercialize the company s flagship liquid biopsy program for breast cancer, while working to position Mammogen as a global leader in women s health. The company has developed a proprietary methodology for early cancer detection using novel messenger RNA (mRNA) biomarkers, which has shown statistical significance towards providing measurable improvement upon current standards of care.

New yorkUnited statesSan diegoUnited kingdomLos angelesMarty keiserBench is one global teamNovartis pharmaceuticalsBench internationalMyriad geneticsCommercial operationsExodx prostateLife scienceOne global teamOne global budgetLiquid biosciences